Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001 | MicrobiomeTrials← Back to trialsNCT07867288
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-10Est. Completion: 2027-03
Enrollment target: 10 participants Locations- Lahey Clinic, Boston, Massachusetts, United States
- Saint Luke's Health System, Kansas City, Missouri, United States
Other microbiome trials you might be interested in
Non-obstructive Hypertrophic Cardiomyopathy
FORTITUDE-HCM is a global, multicenter, double-blind, parallel-group, placebo-controlled Phase 2b study that will assess…
La Jolla, United StatesEst. completion Dec 2026
Symptomatic Hypertrophic Cardiomyopathy (HCM)
The purpose of this study is to collect long-term safety and tolerability data for aficamten.
Birmingham, United StatesCompleted Mar 2029